AXSOME THERAPEUTICS, INC. Amortization of Intangible Assets
AXSOME THERAPEUTICS, INC. (AXSM) reported Amortization of Intangible Assets of $1.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $1.59M, a 0.00% change year-over-year.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $1.57M, a 0.00% change year-over-year.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $1.61M, a 0.00% change year-over-year.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $1.61M, a 0.06% increase year-over-year.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2025 was $6.38M, a 0.27% decline from fiscal 2024.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2024 was $6.39M, a 0.27% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $6.38M, a 54.02% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $4.14M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.59M 10-Q · filed 2026-08-10 | $3.16M 10-Q · filed 2026-08-10 | $4.77M derived: sum of 3 quarters · filed 2026-08-10 | $6.38M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-04 | $3.18M derived: sum of 2 quarters · filed 2026-05-04 | $4.79M derived: sum of 3 quarters · filed 2026-05-04 | $6.38M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.21M derived: sum of 2 quarters · filed 2026-02-23 | $4.80M derived: sum of 3 quarters · filed 2026-08-10 | $6.38M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $1.61M 10-Q · filed 2025-11-03 | $3.20M derived: sum of 2 quarters · filed 2026-08-10 | $4.77M 10-Q · filed 2025-11-03 | $6.38M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $1.59M 10-Q · filed 2026-08-10 | $3.16M 10-Q · filed 2026-08-10 | $4.77M derived: sum of 3 quarters · filed 2026-08-10 | $6.37M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $1.57M 10-Q · filed 2026-05-04 | $3.18M derived: sum of 2 quarters · filed 2026-05-04 | $4.79M derived: sum of 3 quarters · filed 2026-05-04 | $6.38M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.21M derived: sum of 2 quarters · filed 2026-02-23 | $4.80M derived: sum of 3 quarters · filed 2026-02-23 | $6.39M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $1.61M 10-Q · filed 2025-11-03 | $3.20M derived: sum of 2 quarters · filed 2025-11-03 | $4.79M 10-Q · filed 2025-11-03 | $6.39M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $1.59M 10-Q · filed 2025-08-04 | $3.18M 10-Q · filed 2025-08-04 | $4.79M derived: sum of 3 quarters · filed 2026-02-23 | $6.39M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $1.59M 10-Q · filed 2025-05-05 | $3.20M derived: sum of 2 quarters · filed 2026-02-23 | $4.80M derived: sum of 3 quarters · filed 2026-02-23 | $6.39M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.21M derived: sum of 2 quarters · filed 2026-02-23 | $4.80M derived: sum of 3 quarters · filed 2026-02-23 | $6.38M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | $1.61M 10-Q · filed 2024-11-12 | $3.20M derived: sum of 2 quarters · filed 2024-11-12 | $4.77M 10-Q · filed 2024-11-12 | $6.38M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-06-30 | $1.59M 10-Q · filed 2024-08-05 | $3.16M 10-Q · filed 2024-08-05 | $4.77M derived: sum of 3 quarters · filed 2025-02-18 | $6.38M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-03-31 | $1.57M 10-Q · filed 2024-05-06 | $3.18M derived: sum of 2 quarters · filed 2025-02-18 | $4.79M derived: sum of 3 quarters · filed 2025-02-18 | $5.71M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $3.21M derived: sum of 2 quarters · filed 2025-02-18 | $4.14M derived: sum of 3 quarters · filed 2025-02-18 | $4.14M 10-K · filed 2025-02-18 | $4.14M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $1.61M 10-Q · filed 2023-11-06 | $1.61M 10-Q · filed 2022-11-07 | $2.53M derived: sum of 2 quarters · filed 2023-11-06 | $2.53M 10-Q · filed 2023-11-06 | $2.53M 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $926.00K 10-Q · filed 2023-08-07 | $925.65K 10-Q · filed 2022-08-09 | $926.00K 10-Q · filed 2023-08-07 | $925.65K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |